Blue Owl Capital Holdings »

Inozyme Pharma shares owned by Blue Owl Capital Holdings

Quarter-by-quarter ownership of Inozyme Pharma (INZY) shares owned by Blue Owl Capital Holdings from 13F filings

Historical chart of Blue Owl Capital Holdings investment in Inozyme Pharma

Tip: Access up to 7 years of quarterly data

All positions including Inozyme Pharma held by Blue Owl Capital Holdings consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inozyme Pharma by Blue Owl Capital Holdings

Quarter filed Position value Share count Share price at filing
2023-12-31 $5.4M 1.3M 4.26

More positions owned by Blue Owl Capital Holdings

Pliant Therapeutics (PLRX)
Robinhood Mkts Com Cl A (HOOD)
Cullinan Oncology (CGEM)
Tourmaline Bio (TRML)
Klaviyo Com Ser A (KVYO)
Owl Rock Capital Corporation (OBDC)
Repare Therapeutics Ord (RPTX)
Acelyrin (SLRN)
Larimar Therapeutics (LRMR)
Keros Therapeutics (KROS)
Ultragenyx Pharmaceutical (RARE)
Engene Holdings (ENGN)
Syros Pharmaceuticals Com New (SYRS)
Disc Medicine (IRON)
E2open Parent Holdings Com Cl A (ETWO)

View all positions for Blue Owl Capital Holdings

Top funds holding Inozyme Pharma

Samlyn Capital
Eventide Asset Management
NEA Management Company
Vanguard Group
Sphera Funds Management
Samsara BioCapital
Blue Owl Capital Holdings
Millennium Management
Laurion Capital Management
Octagon Capital Advisors
Goldman Sachs Group
Kennedy Capital Management
Overbrook Management Corp.
Citadel Advisors
GSA Capital Partners

View all funds holding Inozyme Pharma